Information de reference pour ce titreAccession Number: | 00000434-201806000-00019.
|
Author: | Singh, Siddharth MD, MS 1,2; Proudfoot, James MS 3; Xu, Ronghui PhD 4; Sandborn, William J. MD 1
|
Institution: | (1)Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA. (2)Division of Biomedical informatics, University of California San Diego, La Jolla, CA, USA. (3)Biostatistics Unit, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, CA, USA. (4)Department of Family Medicine and Public Health and Department of Mathematics, University of California San Diego, La Jolla, CA, USA.
|
Title: | |
Source: | American Journal of Gastroenterology. 113(6):883-889, June 2018.
|
Abstract: | OBJECTIVES: To assess whether obesity may affect response to infliximab, we conducted an individual participant data pooled analysis using data from clinical trials of infliximab in inflammatory bowel diseases (IBD), using the Yale Open Data Access (YODA) Project.
METHODS: We analyzed individual participant data from four clinical trials of infliximab in adults with IBD (ACCENT-I, SONIC, ACT-1, and -2). Patients were categorized as obese (body mass index [BMI] >= 30 kg/m2) vs. non-obese, and by quartiles based on BMI or weight at time of trial entry. Primary outcome was clinical remission (Crohn's disease activity index [CDAI] < 150 or pediatric CDAI <10, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing. Multivariable logistic regression analysis was performed, after adjusting for sex, smoking, disease activity, and concomitant prednisone and/or immunomodulators.
RESULTS: We included 1205 infliximab-treated patients (mean age 37 years, 51.6% males, 14% obese). Obesity was not associated with odds of achieving clinical remission (obese vs. non-obese: adjusted OR, 0.93 [95% CI, 0.47-1.46]; Q4 vs. Q1: aOR, 0.94 [0.61-1.47], p-value for trend = 0.97), clinical response (Q4 vs. Q1: aOR, 0.84 [0.52-1.35], p = 0.45) or mucosal healing (Q4 vs. Q1: aOR, 1.13 [0.55-2.34], p = 0.95). These results were consistent across strata based on disease type (Crohn's disease and ulcerative colitis) and trial design (induction and maintenance therapy).
CONCLUSIONS: Based on individual participant data pooled analysis, obesity is not associated with inferior response to infliximab in patients with IBD. Future studies examining the association between obesity and fixed-dose therapies are warranted.
(C) The American College of Gastroenterology 2018. All Rights Reserved.
|
References: | 1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766-81.
2. Flores A, Burstein E, Cipher DJ, et al. Obesity in inflammatory bowel disease: A marker of less severe disease. Dig Dis Sci. 2015;60:2436-45.
3. Pringle PL, Stewart KO, Peloquin JM, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn's disease. Inflamm Bowel Dis. 2015;21:2304-10.
4. Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110-21.
5. Singh S, Fumery M, Shaffer K, et al. Pre-morbid obesity is associated with increased risk of developing immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2017;152:S976-77.
6. Jain A, Singh S, Martin C, et al. Obesity is associated with worse disease activity in patients with inflammatory bowel diseases: An internet based cohort study. Gastroenterology. 2017;152:S973-74.
7. Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:2857-63.
8. Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology. 2016;55:2191-9.
9. Iannone F, Fanizzi R, Notarnicola A, et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-alpha inhibitor in rheumatoid arthritis patients. Jt Bone Spine. 2015;82:187-91.
10. Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheuma. 2011;63:359-64.
11. Singh S, Facciorusso A, Singh AG, et al. Obesity and response to antitumor necrosis factor-[alpha] agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123. https://doi.org/10.1371/journal....- ouverture dans une nouvelle fenêtre
12. Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?. Eur J Gastroenterol Hepatol. 2013;25:543-9.
13. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19: 2118-24.
14. Passot C, Mulleman D, Bejan-Angoulvant T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. Mabs. 2016;8:1407-16.
15. Wade JR, Parker G, Kosutic G, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015;55:866-74.
16. Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) Project-A mechanism for data sharing. N Engl J Med. 2016;375:403-5.
17. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-44.
18. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105:2085-92.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
20. R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
21. Ottaviani S, Allanore Y, Tubach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther. 2012;14:R115.
22. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955-8.
|
Language: | English.
|
Document Type: | ARTICLE.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0002-9270
|
NLM Journal Code: | 3he, 0421030
|
DOI Number: | https://dx.doi.org/10.1038/s4139...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|